Skip to main content
. 2007 Oct 16;97(8):1124–1134. doi: 10.1038/sj.bjc.6603992

Table 2. Clinical data of patients in the validation group with ovarian adenocarcinomas.

Age (years)
 Median (range) 58 (22–86)
 
Histological type
 Serous 35 (77.8%)
 Mucinous 1 (2.2%)
 Endometrioid 3 (6.7%)
 Clear cell 3 (6.7%)
 Poorly differentiated 1 (2.2%)
 Not specified 2 (4.4%)
 
Histologic grade
 1 4 (9.3)
 2 20 (46.5)
 3 19 (44.2%)
 
FIGO stage
 I 1 (2.2%)
 II 6 (13.3%)
 III 29 (64.4%)
 IV 9 (20.0%)
 
Primary residual tumour
 No 16 (35.6%)
 Yes 28 (62.2%)
 Not specified 1 (2.2%)
 
Adjuvant chemotherapy
 Platinum-containing 34 (75.6%)
 Non platinum-containing 11 (24.4%)
 
Clinical outcome
 Died of ovarian cancer 29 (64.4%)
 Alive 16 (35.6%)